Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008268 · ClinicalTrials.gov registry record · Phase 2
Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00008268: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00008268 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00008268, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Melphalan and colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase II trial to study the effectiveness of melphalan combined with filgrastim in stimulating peripheral stem cells in patients who have multiple myeloma.
Interventions
- DRUG melphalan
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00008268
The ClinicalTrials.gov registry entry for NCT00008268 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which melphalan is the first listed.
NCT00008268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00008268 about?
NCT00008268 is a clinical study titled "Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma". RATIONALE: Melphalan and colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase II trial to study the effectiveness of melphalan combined with filgrastim in stimulating peripheral stem cells in patients who have...
What is the current status of trial NCT00008268?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-08. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00008268?
The interventions under investigation include: melphalan (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00008268?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.